Clinical Trial Update: Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports safety, pharmacokinetics and proof-of-concept results for ARN-509 (apalutamide) in castration-resistant prostate cancer across Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-07-27